~~<i id='C1E9D354F4'><strike id='C1E9D354F4'><tt id='C1E9D354F4'><pre id='C1E9D354F4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：hotspot 2025-09-06 04:30:17 - browse：13391

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Infant mortality in U.S. rose last year for first time in decades: CDC

focus

entertainment

focus

leisure time

explore

focus

NovoNordiskviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnew

WSS

Kaiser's Risant Health gobbled up Geisinger. Who is next?

See how much Covid

With trial win, GSK could get blood cancer drug back on market

How to increase colonoscopy rates? Looks like an AI can help

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Readout LOUD podcast: ESMO highlights & Roivant's big deal

hotspot

entertainment

focus

Affirmative action in medical school literally saved lives

Bill would allow buprenorphine prescription for addiction via telehealth

Affirmative action in medical school literally saved lives

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

In age of alternative facts, a scholarly course on calling out crap

Woman returns to dialysis after doctors remove transplanted pig kidney

Anesthesiologist group: stop taking Ozempic before surgery

Infant mortality in U.S. rose last year for first time in decades: CDC

The high cost of giving birth even with insurance

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

entertainment

Intellia reports positive results for its CRISPR

Kidney transplant patients stopped immunosuppressants in trial

Gene therapy’s promise and the high cost of hope

Cord blood banking comes at a high cost to babies

FDA's Pazdur wants cancer trials to range beyond China alone

ASCO: Palliative care found as helpful given virtually as in person

focus

leisure time

explore

focus